BioSpace News Archive

UCB, a global biopharmaceutical company, announced new long-term data from the BIMZELX® Phase 2b study BE AGILE and its open-label extension.

Seegene Inc. announced on November 10 that it has received an overall rating of ‘B+' in the 2023 ESG evaluation conducted by the Korea Institute of Corporate Governance and Sustainability.

Servier will showcase new data from its vorasidenib clinical development program in a plenary townhall at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO), November 16-19, 2023, in Vancouver, Canada.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication in Molecular Cancer Therapeutics highlighting paxalisib preclinical data stemming from the research collaboration with the Huntsman Cancer Institute at the University of Utah in Salt Lake City, UT.

Precision BioSciences, Inc. announced that the Company will present at the Sidoti November Micro Cap Conference taking place November 15-16, 2023.

2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its third quarter 2023 financial results on Tuesday, November 14, 2023.

Imvax, Inc. today announced two poster presentations at the 2023 Society for NeuroOncology (SNO) 28th Annual Meeting in Vancouver, British Columbia, Canada, from November 15-19, 2023.

MAIA Biotechnology, Inc. announced today that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to its lead asset THIO, a cancer telomere-targeting agent, for the treatment of glioblastoma.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended September 30, 2023 and provided a corporate update.

Pacira BioSciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) to expand the EXPAREL® (bupivacaine liposome injectable suspension) label to include administration in adults as an adductor canal block and a sciatic nerve block in the popliteal fossa.